Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chuikyo Discusses Hirudoid, Gx at 2nd Review Round for FY2018 Fee Schedule Revision
The Central Social Insurance Medical Council, a key reimbursement policy panel better known as Chuikyo, on January 26, held the second round of its final review for the FY2018 medical fee schedule revision in April. Members exchanged opinions over the…
To read the full story
Related Article
- Proper Use of Ethical Moisturizing Agents Added to Supplementary Opinion for FY2018 Reimbursement Reform: Chuikyo
February 1, 2018
- Chuikyo Enters Final Review of FY2018 Fee Schedule Revision; Recommendation Due Out Feb. 7
January 25, 2018
- Chuikyo Plans for FY2018 Fee Schedule Revision Now Up for Public Comments
January 15, 2018
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…